Literature DB >> 26126429

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.

Mohamad Wessam Alnouri1, Stephan Jepards, Alessandro Casari, Anke C Schiedel, Sonja Hinz, Christa E Müller.   

Abstract

Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature has been obtained for the human species. However, preclinical studies are mostly performed in mouse or rat, and standard AR agonists and antagonists are frequently used for studies in rodents without knowing their selectivity in the investigated species. In the present study, we selected a set of frequently used standard AR ligands, 8 agonists and 16 antagonists, and investigated them in radioligand binding studies at all four AR subtypes, A1, A2A, A2B, and A3, of three species, human, rat, and mouse. Recommended, selective agonists include CCPA (for A1AR of rat and mouse), CGS-21680 (for A2A AR of rat), and Cl-IB-MECA (for A3AR of all three species). The functionally selective partial A2B agonist BAY60-6583 was found to additionally bind to A1 and A3AR and act as an antagonist at both receptor subtypes. The antagonists PSB-36 (A1), preladenant (A2A), and PSB-603 (A2B) displayed high selectivity in all three investigated species. MRS-1523 acts as a selective A3AR antagonist in human and rat, but is only moderately selective in mouse. The comprehensive data presented herein provide a solid basis for selecting suitable AR ligands for biological studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26126429      PMCID: PMC4529847          DOI: 10.1007/s11302-015-9460-9

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  78 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

Review 2.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 3.  Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.

Authors:  Peter Jenner
Journal:  Expert Opin Investig Drugs       Date:  2005-06       Impact factor: 6.206

4.  2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors.

Authors:  K N Klotz; M J Lohse; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

Review 5.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

6.  Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.

Authors:  B Grahner; S Winiwarter; W Lanzner; C E Müller
Journal:  J Med Chem       Date:  1994-05-13       Impact factor: 7.446

7.  Molecular cloning and characterization of the human A3 adenosine receptor.

Authors:  C A Salvatore; M A Jacobson; H E Taylor; J Linden; R G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

8.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

9.  Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.

Authors:  John D Salamone; Lyndsey E Collins-Praino; Marta Pardo; Samantha J Podurgiel; Younis Baqi; Christa E Müller; Michael A Schwarzschild; Mercè Correa
Journal:  Eur Neuropsychopharmacol       Date:  2012-09-01       Impact factor: 4.600

10.  Impaired glucose tolerance in the absence of adenosine A1 receptor signaling.

Authors:  Robert Faulhaber-Walter; William Jou; Diane Mizel; Lingli Li; Jiandi Zhang; Soo Mi Kim; Yuning Huang; Min Chen; Josephine P Briggs; Oksana Gavrilova; Jurgen B Schnermann
Journal:  Diabetes       Date:  2011-08-10       Impact factor: 9.461

View more
  49 in total

Review 1.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

2.  Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms.

Authors:  Jesse Lea Carlin; Shalini Jain; Elizabeth Gizewski; Tina C Wan; Dilip K Tosh; Cuiying Xiao; John A Auchampach; Kenneth A Jacobson; Oksana Gavrilova; Marc L Reitman
Journal:  Neuropharmacology       Date:  2016-11-30       Impact factor: 5.250

Review 3.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

Review 4.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

5.  Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution.

Authors:  Dilip K Tosh; Veronica Salmaso; Harsha Rao; Amelia Bitant; Courtney L Fisher; David I Lieberman; Helmut Vorbrüggen; Marc L Reitman; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

6.  Functional coupling between adenosine A1 receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding or [35S]GTPγS/immunoprecipitation assay.

Authors:  Yuji Odagaki; Masakazu Kinoshita; Toshio Ota; J Javier Meana; Luis F Callado; Isao Matsuoka; Jesús A García-Sevilla
Journal:  Purinergic Signal       Date:  2018-02-28       Impact factor: 3.765

7.  Adenosine receptors: regulatory players in the preservation of mitochondrial function induced by ischemic preconditioning of rat liver.

Authors:  Filipe V Duarte; João A Amorim; Ana T Varela; João S Teodoro; Ana P Gomes; Rodrigo A Cunha; Carlos M Palmeira; Anabela P Rolo
Journal:  Purinergic Signal       Date:  2016-11-15       Impact factor: 3.765

8.  Tritium-labeled agonists as tools for studying adenosine A2B receptors.

Authors:  Sonja Hinz; Wessam M Alnouri; Ulrich Pleiss; Christa E Müller
Journal:  Purinergic Signal       Date:  2018-05-11       Impact factor: 3.765

9.  Activation of adenosine A2A or A2B receptors causes hypothermia in mice.

Authors:  Jesse Lea Carlin; Shalini Jain; Romain Duroux; R Rama Suresh; Cuiying Xiao; John A Auchampach; Kenneth A Jacobson; Oksana Gavrilova; Marc L Reitman
Journal:  Neuropharmacology       Date:  2018-03-13       Impact factor: 5.250

10.  Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology.

Authors:  Theodore E Liston; Sonja Hinz; Christa E Müller; Deborah M Holstein; Jay Wendling; Roger J Melton; Mary Campbell; William S Korinek; R Rama Suresh; Dane A Sethre-Hofstad; Zhan-Guo Gao; Dilip K Tosh; Kenneth A Jacobson; James D Lechleiter
Journal:  Purinergic Signal       Date:  2020-10-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.